Amgen Launches Rituxan Rival In US
As Company Reflects On Future Of Biosimilars In US
Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.
